TABLE 2.

Lymphocyte transformation test and PBMC ELIspot

ID	Lymphocyte Transformation Test									Piperacillin ELIspot
	Control	Piperacillin							Tetanus Toxoid	IFN-γ, 2 mM	IL-13, 2 mM
		0.06 mM	0.13 mM	0.25 mM	0.5 mM	1 mM	2 mM	4 mM
	cpm
Piperacillin-hypersensitive patients
1	2957	<2a	<2	2.3	2.8	8.3	6.3	7.0	23.4	+++b	++
2	804	2.1	2.8	6.5	5.9	5.7	4.4	1.8	24.0	++	++
3	2138	<2	<2	<2	<2	4.8	3.1	2.6	22.1	+++	++
4	1787	<2	2.4	3.6	6.9	6.7	6.8	4.5	13	+	+
5	1685	30.0	39.8	47.2	62.5	60.0	55.0	41.1	35.4	+++	+++
6	1436	5.6	11.5	16.0	20.1	31.4	26.7	28.1	16.0	++	+
7	1222	<2	<2	<2	2.8	3.7	6.3	6.6	27.3	++	−
8	1017	<2	<2	<2	2.5	7.7	5.9	10.4	47	++	−
Piperacillin-tolerant patients
1	542	<2	<2	<2	<2	<2	<2	<2	21.8	−	−
2	301	<2	<2	<2	<2	<2	<2	<2	11.1	−	−
3	980	<2	<2	<2	<2	<2	<2	<2	8.9	−	−
4	163	<2	<2	<2	2.2	<2	<2	<2	3.2	−	−
5	233	<2	<2	<2	<2	<2	<2	<2	28.1	−	−

^a Data presented as stimulation index (cpm in test incubations/cpm in control incubations).

^b Spot-forming cells after piperacillin (2 mM) treatment, with control subtracted: −, <10; +, 10–30; ++, 30–100; +++, >100.